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We report on four families affected by a clinical presentation of complex hereditary spastic paraplegia (HSP) due to recessivemutations in
DDHD2, encoding one of the three mammalian intracellular phospholipases A1 (iPLA1). The core phenotype of this HSP syndrome
consists of very early-onset (<2 years) spastic paraplegia, intellectual disability, and a specific pattern of brain abnormalities on cerebral
imaging. An essential role for DDHD2 in the human CNS, and perhaps more specifically in synaptic functioning, is supported by
a reduced number of active zones at synaptic terminals in Ddhd-knockdown Drosophila models. All identified mutations affect the
protein’s DDHD domain, which is vital for its phospholipase activity. In line with the function of DDHD2 in lipid metabolism and
its role in the CNS, an abnormal lipid peak indicating accumulation of lipids was detected with cerebral magnetic resonance spectros-
copy, which provides an applicable diagnostic biomarker that can distinguish the DDHD2 phenotype from other complex HSP pheno-
types.We show thatmutations inDDHD2 cause a specific complexHSP subtype (SPG54), thereby linking amember of the PLA1 family to
human neurologic disease.Hereditary spastic paraplegia (HSP) is a genetically hetero-
geneous group of neurodegenerative disorders character-
ized by a length-dependent, distal axonopathy of fibers
of the corticospinal tract, which clinically leads to lower-
limb spasticity and weakness. In pure HSP, symptoms are
more or less restricted to corticospinal-tract dysfunction,
whereas in complex HSP, the disease is more widespread
and encompasses additional neurologic and non-neuro-
logic symptoms. Inheritance can follow anX-linked, domi-
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Figure 1. Pedigrees of Families 1–4, Photographs of the Face, and Chromatograms Showing Sanger Confirmation of the DDHD2
Mutations
Arrows indicate the individuals on whom exome sequencing was performed. The following abbreviations are used: M, mutant allele; ,
wild-type allele; and C, control.
(A) Family 1 (family identifier: W10-1338) has an affected sister and brother and compound heterozygous frameshift mutations
c.1804_1805insT (p.Thr602Ilefs*18) and c.2057delA (p.Glu686Glyfs*35).
(B) Family 2 has an affected sister and brother and compound heterozygous frameshift and missense mutations c.1386dupC (p.Ile463-
Hisfs*6) and c.1978G>C (p.Asp660His).
(C) Consanguineous family 3 has seven affected individuals and homozygous mutation c.1546C>T (p.Arg516*). Pedigree numbering is
according to the original pedigree by Al-Yahyaee et al.8
(D) Consanguineous family 4 (family identifier: W12-0041) has one affected male individual and homozygous mutation c.859C>T
(p.Arg287*).
(E) The protein structure of DDHD2 includes its four domains (WWE, lipase, SAM, and DDHD), and the position of all identified muta-
tions are indicated.HSP; MIM 604360),2 ZFYVE26 (SPG15, <3% of autosomal-
recessive HSP; MIM 270700),2 SPG21 (in an old-order
Amish population; MIM 248900),4 GJC2 (SPG44, one
family reported; MIM 613206),5 and AP4B1 (SPG47, two
families reported; MIM 607245).6,7
We ascertained two families affected by a complex HSP
form consisting of a combination of early-onset spastic
paraplegia and intellectual disability (ID) and characterized
by a marked thin corpus callosum and subtle periventricu-
lar white-matter hyperintensities onMRI and an abnormal
lipid peak on cerebral protonmagnetic resonance spectros-
copy (MRS). This study was approved by theMedical Ethics
Committee of the Radboud University Nijmegen Medical
Centre, and all participants signed informed consent.
Exome sequencing was performed on genomic DNA of
the affected boy from family 1 and on both siblings and
the father from family 2 (Figure 1). For families 1 and 2,1074 The American Journal of Human Genetics 91, 1073–1081, Decegenomic DNA was captured with an Agilent SureSelect
Human All Exon 50 Mb Kit (Agilent Technologies, Santa
Clara, CA, USA). Captured DNA of family 1 was sequenced
on one-fourth of a sequence slide on a SOLiD 4 System and
aligned to the reference human genome (hg19) (Life Tech-
nologies, Carlsbad, CA, USA). The exome-sequencing
experiment and analysis pipeline were previously
described by Vissers et al.9 For family 2, captured DNA
was sequenced on Illumina HiSeq 2000 according to the
manufacturer’s (Illumina, San Diego, CA, USA) protocol.
The Fastx toolkit was used for removing adaptor sequences
and trimming sequence reads. The Burrows-Wheeler
Aligner 0.5.910 and Genome Analysis Toolkit11 were used
for aligning reads to the reference human genome
(hg19). Single-nucleotide variants and indels were called
with SAMtools12 and annotated with ANNOVAR13 and
custom scripts. For both families, variant prioritizationmber 7, 2012
(including indels) excluded all variants present in fewer
than 20% of reads, as well as all nongenic, intronic (other
than canonical splice sites) variants and variants leading to
synonymous amino acid changes. Next, variants with
a frequency > 1% in dbSNP v.134 or the Nijmegen local
variant database (~270 exome-sequencing experiments)
were excluded for family 1. For family 2, variants present
in dbSNP v.132 or control samples from exome experi-
ments sequenced through the FORGE project (~400
exome-sequencing experiments) were excluded. Candi-
date mutations were selected under the assumption of an
autosomal-recessive disease model (Tables S1 and S2, avail-
able online). There was overlap for candidate mutations
in only one gene, DDHD2 (RefSeq accession number
NM_015214.2), between both families. For family 1,
variant selection resulted in candidate recessive mutations
in seven genes; the most striking were two heterozygous
mutations in DDHD2 because they both result in a shift
of the open reading frame. In family 2, compound hetero-
zygous mutations in only one gene, DDHD2, fit a recessive
model after comparison of variants of all three family
members (Figure S1). Sanger sequencing showed that the
respective mutations segregated with the phenotype in
both families (Figures 1A and 1B).
In family 1, compound heterozygous frameshift muta-
tions c.1804_1805insT and c.2057delA were detected in
DDHD2 (Figure 1A). At the protein level, both mutations
result in a premature termination codon (PTC), p.Thr602I-
lefs*18 (c.1804_1805insT) and p.Glu686Glyfs*35
(c.2057delA), within the DDHD domain, which is located
at the C-terminal end of the protein (Figure 1E). In
family 2, a compound heterozygous frameshift mutation,
c.138dupC, and a missense mutation, c.1978G>C, were
identified (Figures 1B and 1E). At the protein level, the
frameshift mutation introduces a PTC (p.Ile463Hisfs*6)
before the DDHD domain, and the missense mutation
results in the substitution of a histidine for an aspartic
acid (p.Asp660His) within the RIDYXL motif, which is
conserved among the DDHD domains of the three human
PLA1s, DDHD1, DDHD2, and SEC23IP (Figure S2A). In
addition, the aspartic acid at position 660 is conserved
down to Drosophila melanogaster (Figure S2B). The
c.1978G>C mutation was found once in the National
Heart, Lung, and Blood Institute (NHLBI) Exome Variant
Server database consisting of 13,006 alleles, but not in
our local SNP database consisting of 2,302 alleles. The
other mutations were not present in either database.
DDHD2 is located in chromosomal region 8p11.23.
Previously, in a large consanguineous Omani family
(family 3) affected by a similar phenotype, the genetic
defect was mapped to a 9 cM interval on chromosome
8p.8 This region (SPG18 [MIM 611225]) encompasses
DDHD2 and ERLIN2,8,14,15 but mutation analysis and
mRNA gene-expression analysis excluded mutations in
ERLIN2 as disease causing, whereas Sanger sequencing of
DDHD2 revealed a homozygous c.1546C>T mutation.
This mutation introduces a PTC resulting in p.Arg516* atThe American Jouthe very beginning of the DDHD domain (Figure 1C). A
screen of all affected and unaffected individuals showed
complete segregation of this mutation with the disease
phenotype in this family. The p.Arg516* change was
absent from 200 alleles of healthy ethnically matched
controls and was observed once in the heterozygous state
in the NHLBI Exome Variant Server database but was
absent from our local SNP database.
In order to further determine the occurrence and pheno-
typic spectrum of the DDHD2 mutations, we sequenced
the protein-coding sequence of DDHD2 in 55 additional
complex-HSP-affected individuals in whom SPG11 muta-
tions were excluded and who had a family history sugges-
tive of recessive inheritance. This resulted in the identifica-
tion of one further homozygous mutation in an affected
male individual from a consanguineous Iranian family.
This homozygous C-to-T substitution in exon 9 at c.859
introduces a PTC at amino acid position 287 of the protein
(family 4, Figure 1D).
Reviewing the phenotypic features of all four families
revealed psychomotor delay that develops into intellectual
disability and very early-onset, progressive spasticity
(Table 1). The first symptoms of spasticity of the affected
individuals became apparent before the age of 2 years.
Foot contractures developed as a result of progressive and
pronounced spasticity. In addition, strabismus and dysar-
thria were present in 9 out of 12 individuals and were
frequently accompanied by dysphagia. Of note, optic-
nerve hypoplasia was present in three out of five individ-
uals who had undergone thorough ophthalmologic
evaluation. Cerebral imaging gave a consistent pattern of
brain abnormalities composed of a marked thin corpus cal-
losum combined with subtle periventricular white-matter
hyperintensities (Figure 2 and Figures S3–S6). In five
affected individuals from families 1, 2, and 4, cerebral
protonMRS was performed, and this revealed an abnormal
spectrum with a lipid peak (1.3 ppm) showing the highest
intensity around the basal-ganglia and thalamus area
(Figure 2C and Figures S3, S4, and S6). This peak is similar
to the characteristic, abnormal lipid peak seen in Sjo¨gren-
Larssen syndrome16 and is indicative of abnormal brain
lipid accumulation. Furthermore, in two male individuals
from families 1 and 2, a syrinx was observed on spinal
MRI (Figure 2D and Figure S7).
Four of the six mutations identified are predicted to
introduce a premature termination codon into the
DDHD2 mRNA open reading frame. Three of these are
positioned more than 55 nt before the last exon-exon
boundary and hence might give rise to nonsense-mediated
RNA decay (NMD). To test this prediction, we measured
DDHD2 mRNA levels in Epstein-Barr-virus-transformed
lymphoblastoid cell lines of the affected individuals from
family 1 and 4 and in a cultured fibroblast cell line from
individual IV-10 in family 3 by real-time quantitative
PCR analysis. We observed that in affected individuals of
family 1, expression levels of DDHD2 mRNA were 84%
of those of the eight control individuals (p ¼ 0.04;rnal of Human Genetics 91, 1073–1081, December 7, 2012 1075
Table 1. Phenotype of Individuals with DDHD2 Mutations
Family 1 Family 2 Family 3a Family 4
TotalII-1 II-2 II-1 II-2 IV-3 IV-4 IV-10 IV-11 IV-12 IV-13 V-30 II-1
Descent Dutch Filipino Canadian Oman Iran











Gender F M F M  M F F F M F M 
Age at investigation
(years)
5 3 10 7  10 21 15 11 10 8 30 
Clinical Features
ID and/or DD þ þ þ þ þ þ þ þ þ þ þ þ 12/12
Hypomimia   þ þ        þ 3/12
Strabismus   þ þ þ þ þ þ þ þ N/A þ 9/12
Optic-nerve hypoplasia þ þ   N/A N/A N/A N/A N/A N/A N/A þ 3/5
Dysartria   þ þ þ þ þ þ þ þ N/A þ 9/12
Dysphagia    þ   þ þ þ þ þ  6/12
Constipation þ þ þ þ þ  þ þ     7/12
Urinary incontinence þ þ þ þ         4/12
Fecal incontinence þ þ þ          3/12
Upper limbs
Spasticity   moderate moderate mild mild  mild     5/12
Distal weakness   þ þ        þ 3/12
Rigidity    þ        þ 2/12
Lower limbs
Spastic paraplegia þ þ þ þ þ þ þ þ þ þ þ þ 12/12
Hyperreflexia þ þ þ þ þ þ þ þ þ þ þ þ 12/12
Distal weakness   þ þ þ þ þ þ þ þ N/A þ 9/12
Pes cavus       þ þ     2/12
Foot contractures þ þ þ þ þ þ þ þ þ þ þ þ 12/12
Radiological Findings
Thin corpus callosum þ þ þ þ þ þ N/A þ þ þ þ þ 11/11
PWMH þ þ þ þ þ þ N/A þ þ þ þ þ 11/11
Lipid peakb þ þ þ þ N/A N/A N/A N/A N/A N/A N/A þ 5/5
Syrinx  þ N/A þ N/A N/A N/A N/A N/A N/A N/A  2/4
Mitochondrial
Function
normal N/A normal normal N/A N/A N/A N/A N/A N/A N/A N/A 0/3
RefSeq accession number NM_015214.2 was used in namingmutations. The following abbreviations are used:þ, presence of clinical features; –, absence of clinical
features; F, female; M, male; ID, intellectual disability; DD, developmental delay; PWMH, periventricular white-matter hyperintensities; and N/A, not available.
aFamily 3 has previously been described by Al-Yahyaee et al.8
bLipid peak at 1.3 ppm (as measured by proton MRS) and the highest signal intensity in the basal-ganglia and thalamus area.Figure S8). Because NMD usually results in 15%–58%
expression as compared to controls,17,18 this suggests
NMD for only one of the two alleles, which is in line1076 The American Journal of Human Genetics 91, 1073–1081, Decewith the fact that one of the mutations, c.2057delA, is
located in the last coding exon and hence does not target






Figure 2. CNS Imaging of Individual II-2
of Family 1
(A) Midsagittal T1-weighted MRI of the
brain shows a marked thin corpus cal-
losum (arrow).
(B) Transverse T2-weighted MRI of the
brain shows subtle white-matter hyperin-
tensities (arrows).
(C) Proton MRS obtained at a magnetic
field of 1.5 tesla. Voxel was fixed just
cranial of the basal-ganglia and thalamus
area, of which proton MRS at long echo
time (144 ms) was obtained. It shows
the prominent pathologic lipid peak at
1.3 ppm (arrow), apart from the common
spectral peaks of choline (Cho), creatine
(Cr), and N-acetylaspartate (NAA).
(D) Sagittal T2-weighted MRI of the spine
shows a spinal syrinx (arrow). Similar brain
abnormalities and proton MRS were found
in the other families (Figures S3–S7).to alter the protein sequence of the last 14 amino acids, of
which seven are conserved down to the Drosophila
melanogaster, of the DDHD2 domain, (Figure S2B). For
family 4, 46% expression of DDHD2 mRNA levels was
observed (p < 0.0001), which suggests that both alleles
are subject to NMD. For individual IV-10 of family 3, we
found that DDHD2 mRNA expression was eight times
lower than in two healthy control samples. As expected
for mutations that result in NMD, DDHD2 mRNA levels
in families 1 and 4 were restored to normal when cells of
affected individuals were treated with protein-translation
inhibitor cycloheximide (Figure S8). Further mRNA studies
comparing DDHD2 expression levels among different
human tissues showed markedly high expression in the
adult CNS, which is in line with the observed phenotypic
features (Figure S9).
DDHD2 (DDHD-domain-containing 2) belongs to the
mammalian intracellular phospholipase A1 (iPLA1) family.
This protein family consists of three paralogs—DDHD1,
DDHD2, and SEC23IP—that share a conserved lipase motif
(GxSxG) and a DDHD domain. They exhibit enzymatic
activity and hydrolyze an acyl group of phospholipids at
the sn-1 position. All three members have been implicated
in organelle biogenesis and membrane trafficking.19–22
From the N terminus to the C terminus, DDHD2 contains
aWWE domain, a GxSxG lipase motif, a sterile alphamotif
(SAM), and a DDHD domain (Figure 1E). The DDHD
domain is a multifunctional domain that, together withThe American Journal of Human Geneticthe SAM domain, is essential for its
phospholipase activity.19 DDHD2
preferentially hydrolyzes phospha-
tidic acid but also exhibits activity
toward several other phospholipids,
such as phosphatidylethanolamine.
The protein localizes to the cis-Golgi
and also to the endoplasmic-
reticulum (ER)-Golgi intermediatecompartment.19,21,23 Furthermore, RNA-interference
experiments in cellular systems have indicated functions
for DDHD2 in transport from the Golgi to the plasma
membrane.19 In view of this, it has been hypothesized
that DDHD2 determines (local) membrane curvature and
facilitates membrane and vesicle fusion by the modifica-
tion of membranes through phospholipid hydrolysis.23
Given the function of DDHD2 in phospholipid metabo-
lism and the observed lipid accumulation by brain proton
MRS, we investigated fibroblasts of affected individuals for
abnormalities in lipid metabolism. Oil-red-O staining of
fibroblasts from individuals II-1 of family 1, II-2 of family 2,
and II-1 of family 4 showed no difference in appearance
and number of lipid droplets between affected individuals
(n ¼ 3) and controls (n ¼ 3) (Figure S10). We also investi-
gated the effect of the mutations on cellular organelle
morphology because DDHD2 has been described as an
intracellular-transport protein involved in organelle
biogenesis.19–22 Electron microscopy of fibroblasts from
individuals II-1 of family 1, IV-10 of family 3, and II-1 of
family 4 showed a normal appearance of the ER, golgi,
mitochondria, and nucleus in fibroblasts of affected indi-
viduals (n ¼ 3) and no difference in organelle distribution
between fibroblasts of affected and control individuals
(n ¼ 4) (Figure S11). In all fibroblast cell lines, dense lyso-
somes and small empty vacuoles could be found in various
amounts; however, in a minority of cells from individual
II-1 of family 1, large empty vacuoles were localized ats 91, 1073–1081, December 7, 2012 1077
the cellular membrane and were surrounded by a single
membrane and glycogen (Figure S11I). These large vacu-
oles were not observed in fibroblast cells of any of the
other affected individuals or in the control individuals
and are thus of uncertain significance. These results
do not support gross abnormalities in lipid metabolism
or organelle morphology in cultured fibroblast cells of
affected individuals.
To further demonstrate an essential function for DDHD2
in the CNS, we targeted the Drosophila DDHD2 ortholog,
CG8552, by using the UAS-Gal4 system24 and inducible
RNA interference (RNAi)25 with the pan-neuronal UAS-
dicer2; elav-Gal4 driver. Of note, CG8552 (from here on
referred to as Ddhd) is equally related to DDHD2 and
its paralog SEC23IP, encoding one of the other human
intracellular iPLAs1. Three different Ddhd RNAi lines
(vdrcGD35956, vdrcGD35957, and vdrcKK108121), repre-
senting two nonoverlapping RNAi target sequences, were
utilized and compared to two control fly lines that repre-
sent the same genetic background as the mutant lines
(vdrcGD60000 for vdrcGD35956 and vdrcGD35957;
vdrcKK60100 for vdrcKK108121). The effect of neuron-
specific Ddhd knockdown on synaptic and subsynaptic
organization was studied at the neuromuscular junction
(NMJ). The Drosophila larval NMJ is a well-established
synaptic model system that shares major features with
central excitatory synapses in the mammalian brain26
and has successfully been used for characterizing a number
of Drosophila models of neurological diseases, including
HSP and ID disorders.27–30 Staining of these synapses
with an antibody against the scaffolding protein disc
large 1 (dlg1) highlights the overall NMJ morphology.
Quantitative measurement of the amount of synaptic
branches and branching points revealed normal overall
architecture of synaptic terminals in all three knockdown
conditions. Synaptic terminals of one of the knockdown
lines (vdrcKK108121) were smaller, as reflected in both
area (91%, p ¼ 0.012) and length (88%, p ¼ 0.001)
(Figure S12). We also determined the amount of chemical
synapses, so-called active zones, within synaptic terminals,
which represent the presynaptic sites of neurotransmitter
release. Active zones were visualized with an antibody
against the active-zone component bruchpilot (brp).
Knockdown of Ddhd resulted in a mild but highly
significant decrease in active-zone number per synaptic
terminal as compared to the appropriate genetic-back-
ground controls. This phenotype was consistent in
all three RNAi lines (vdrcGD35956, 90%, p ¼ 0.029;
vrdcGD35957, 80%, p < 0.0001; and vdrcKK108121,
88%, p ¼ 0.002 [Figure 3]). No obvious motor abnormali-
ties were observed in the three knockdown lines of
2- and 10-day-old flies. Because brp and active zones are
crucial for synaptic transmission and plasticity,31 these
observations support an essential role for human DDHD2
in synaptic organization and transmission.
We also compared the clinical characteristics of the
emerging phenotype of recessive mutations in DDHD2 to1078 The American Journal of Human Genetics 91, 1073–1081, Dececomplex HSP phenotypes that give rise to autosomal-reces-
sive spastic paraplegia with a thin corpus callosum and
white-matter abnormalities, i.e., SPG11, SPG15, SPG21,
SPG44, and SPG47. This shows a clear clinical overlap
between the phenotype of recessive DDHD2 mutations
and those of SPG11 (mutations in SPG11), SPG15 (muta-
tions in ZFYVE26), and SPG47 (mutations in AP4B1).
However, individuals with both SPG11 and SPG15 show,
in general, a later age of onset of spasticity, namely in
the second decade of life. Although individuals with
SPG47 do show onset in the first decade of life, they
present with more severe ID than do the affected individ-
uals in our families. The overlap with individuals with
SPG21 and SPG44 is limited to the brain pattern of
a thin corpus callosum and white-matter abnormalities.5
The proteins encoded by SPG11, ZFYVE26, and AP4B1—
spatascin, spastizin, and AP4B1 respectively—are all
proposed to be involved in intracellular trafficking.3,32,33
The overlap in function between these three proteins
and DDHD2 might relate to the phenotypic overlap.
Notably, abnormal lipid accumulation on MRS has not
been reported in any of these complex autosomal-recessive
HSPs,34–36and this finding therefore represents a valuable
parameter for distinguishing the phenotype of recessive
DDHD2mutations from those of the other complex HSPs.
In conclusion, we identified recessive mutations in
DDHD2, encoding an iPLA1, and have defined a complex
form of HSP, designated SPG54. The core phenotype of
the mutations in DDHD2 consists of very early onset of
spasticity, ID, and a specific pattern of structural and meta-
bolic brain abnormalities; the latter represents a useful dis-
tinguishing biomarker in clinical evaluation. An essential
role for DDHD2 in lipid metabolism in the CNS is under-
lined by lipid accumulation that we observed in the brains
of affected individuals, by markedly high expression of
DDHD2 mRNA in the human CNS, and by the reduced
number of active zones at synaptic terminals of the
Drosophila Ddhd-knockdown nervous system.Supplemental Data
Supplemental Data include 12 figures and 2 tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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Figure 3. Synapse Morphology and Organization at the Drosophila NMJ of Control and Ddhd-Knockdown Flies
Three different RNAi lines, vdrcGD35956, vdrcGD35957, and vdrcKK108121, from the Vienna Drosophila Research Center, were used
and compared to their genetic background lines, vdrcGD60000 (for vdrcGD35956 and vdrcGD35957) and vdrcKK60100 (for
vdrcKK108121). RNAi was induced with the pan-neuronal UAS-dicer2; elav-Gal4 driver. Drosophilamuscle 4 type 1b NMJs were analyzed
as previously described.30
(A) Anti-dlg1 (upper panel) and anti-brp immunolabeling (middle panel) at the NMJ of control (vdrcGD60000) and Ddhd-knockdown
(vdrcGD35956) larvae, as well as output of computer-assisted analysis with an in house-developedmacro (bottompanel). Each white dot
represents one active zone.
(B) Quantification of active zones shows a significant reduction in all three RNAi lines compared to their genetic-background controls.
The p values are from two-sided t tests. Error bars indicate the SEM. The following abbreviation is used: n, number of quantified synaptic
terminals.(2010(1)-30 to A.P.M.d.B. and 2009(1)-22 to B.B.A.d.V.). The
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Web Resources
The URLs for data presented herein are as follows:
FASTX-Toolkit, http://hannonlab.cshl.edu/fastx_toolkit/
NHLBI Exome Variant Server Exome Sequencing Project, http://
evs.gs.washington.edu/EVS/
Online Mendelian Inheritance in Man (OMIM), http://www.
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